Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

527
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
527
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Culture-negative Refractory Brain Abscess Presumed to be Caused by Listeria Monocytogenes via a Pulmonary Arteriovenous Malformation.

Internal medicine (Tokyo, Japan)·2026
Same author

Association Between the Japanese Version of Montreal Cognitive Assessment Tasks and Driving as the Primary Mode of Transport Among Community-Dwelling Older Adults.

Canadian geriatrics journal : CGJ·2026
Same author

Neuromyelitis optica spectrum disorder in a patient with neurofibromatosis type 1 mimicking spinal cord infarction.

Practical neurology·2026
Same author

Effects of exercise intervention according to functional decline risk before and after the study among community-dwelling older adults.

The journal of medical investigation : JMI·2026
Same author

Expert perspectives on Myalgic encephalomyelitis/chronic fatigue syndrome - Insights from the 3<sup>rd</sup> International Conference of the Charité Fatigue Center.

Autoimmunity reviews·2026
Same author

[A female case of phospholipase A2 group VI-associated neurodegeneration with childhood onset and long-term follow-up until 49 years of age].

Rinsho shinkeigaku = Clinical neurology·2026

相关实验视频

Updated: May 5, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K

在多发性硬化症治疗中使用ofatumumab,残疾累积.

Masahiro Mimori1, Atsuko Katsumoto2, Tomoko Okamoto2

  • 1Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.

Journal of the neurological sciences
|December 21, 2024
PubMed
概括

在患有多发性硬化症 (MS) 的严重残疾患者 (EDSS分数高) 中,ofatumumab的效果可能较低. 在EDSS得分较低的多发性硬化患者中,早期开始治疗可能会导致更好的结果.

关键词:
疾病修饰药物 疾病修饰药物这就是Ofatumumabumab.渐进的多发性硬化症 渐进的多发性硬化症复发性复发性复发性多发性硬化症

更多相关视频

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

5.4K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.3K

相关实验视频

Last Updated: May 5, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

5.4K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.3K

科学领域:

  • 神经学 神经学
  • 免疫学 免疫学 免疫学

背景情况:

  • 奥法图穆马布在减少复发率和多发性硬化症 (MS) 中的残疾进展方面已经证明有效.
  • 然而,它在严重残疾患者中的有效性,以高扩展残疾状态量表 (EDSS) 评分为准,需要进一步调查.

研究的目的:

  • 为了评估ofatumumab治疗在MS患者高EDSS得分和延长疾病持续时间的结果.
  • 为了确定与这种患者群体中ofatumumab反应相关的因素.

主要方法:

  • 在日本对多发性硬化症患者接受了ofatumumab治疗的回顾性队列研究.
  • 根据连续性,复发与EDSS恶化,以及在12个月后不依赖复发活动的进展 (PIRA),患者被分类为治疗反应或治疗耐药.
  • 使用后勤回归分析来确定ofatumumab反应的预测因素.

主要成果:

  • 分析了70名患者 (39例复发性复发,31例二次进展性多发性硬化症) 的EDSS中位数为4.5.
  • 超过一半 (56%) 的患者被归类为耐治疗,二次进展性多发性硬化 (81%) 与复发性复发性多发性硬化 (33%) 相比,耐药性率更高.
  • 较高的EDSS分数和实现无疾病活动证据 (NEDA-3) 是与ofatumumab反应相关的独立因素.

结论:

  • 在具有更高EDSS分数的MS患者中,ofatumumab治疗结果可能不那么有利.
  • 在EDSS得分较低的患者中,较早开始使用atumumab可能会带来更有益的效果.